Wider Use Sought for Xarelto (Rivaroxaban)
Anticoagulant drug rejected for ACS patients earlier this month (Mar. 8)
According to a Reuters report, two phase III trials have been initiated to expand the use of the anticoagulant drug Xarelto (rivaroxaban). One study is evaluating the drug in patients with chronic heart failure and significant coronary artery disease, and the other study involves patients receiving percutaneous coronary intervention (stents).
Xarelto was co-developed by Bayer in Germany and Johnson & Johnson in the U.S. The drug is already approved for several uses, including stroke prevention in patients with atrial fibrillation.
Earlier this month, the FDA denied approval for wider use of Xarelto to reduce the risk of heart attacks and strokes in patients with acute coronary syndrome.